Blodcancerregistret 2015
PUBLIKATIONER
AML
Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å, Möllgård L, Uggla
B, Wennström L, Wahlin A, Höglund M, Juliusson G, Stockelberg D, Lehmann S. Characterization
and prognostic features of secondary acute myeloid leukemia in a population-based setting: A
report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015 Mar;90(3):208-14. doi:
10.1002/ajh.23908. Epub 2015 Jan 16. PMID: 25421221
Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf A, Lehmann S, Möllgård
L, Peterson S, Stockelberg D, Uggla B, Vennström L, Wahlin A, Höglund M, Juliusson G. Failure
matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor
prognosis in a population-based series of acute myeloid leukaemia. Eur J Haematol. 2014 Sep
8. doi: 10.1111/ejh.12446. [Epub ahead of print] PMID: 25200361
Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf A, Hulegårdh E, Lehmann
S, Möllgård L, Nilsson C, Peterson S, Stockelberg D, Uggla B, Wennström L, Wahlin A, Höglund M,
Juliusson G. Incidence and prognostic significance of karyotypic subgroups in older patients
with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J. 2014
Feb 28;4:e188. doi: 10.1038/bcj.2014.10. PMID: 24583534
Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M; Swedish Acute Leukemia Registry
Group.Acute myeloid leukemia in the real world: why population-based registries are needed.
Blood. 2012 Apr 26;119(17):3890-9. Epub 2012 Mar 1.
Juliusson G, Karlsson K, Lazarevic VL, Wahlin A, Brune M, Antunovic P, Derolf A, Hägglund H,
Karbach H, Lehmann S, Möllgård L, Stockelberg D, Hallböök H, Höglund M; for the Swedish
Acute Leukemia Registry Group, the Swedish Acute Myeloid Leukemia Group, the Swedish Adult
Acute Lymphoblastic Leukemia Group. Hematopoietic stem cell transplantation rates and longterm survival in acute myeloid and lymphoblastic leukemia: Real-World Population-Based
Data From the Swedish Acute Leukemia Registry 1997-2006. Cancer. 2011 Sep
15;117(18):4238-4246. doi: 10.1002/cncr.26033. Epub 2011 Mar 8
Juliusson G; Swedish AML Group. Most 70- to 79-year-old patients with acute myeloid
leukemia do benefit from intensive treatment. Blood. 2011 Mar 24;117(12):3473-4.
Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, Derolf AR, Stockelberg D,
Tidefelt U, Wahlin A, Wennström L, Höglund M, Juliusson G. Continuing high early death rate in
acute promyelocytic leukemia: a population-based report from the Swedish Adult
Acute Leukemia Registry. Leukemia. 2011 Jul;25(7):1128-34. doi: 10.1038/leu.2011.78. Epub
2011 Apr 19
Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy:
an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk. 2011
Jun;11 Suppl 1:S54-9. Epub 2011 May 4.
Juliusson G, Antunovic P, Derolf Å, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A,
Höglund M. Age and Acute myeloid leukemia. Real world data on decision to treat and
outcomes from the Swedish Acute Leukaemia Registry. Blood 2009: 113:4179-4187; e-pub Nov
2008.
Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglund M, Karlsson K, Stockelberg D,
Wahlin A, Åström M, Arnesson C, Brunell-Abrahamsson U, Carstensen J, Fredriksson E,
Holmberg E, Nordenskjöld K, Wiklund F, for the Swedish Adult Acute Leukemia Registry Group.
Attitude Towards Remission Induction for Elderly Patients with Acute Myeloid Leukemia
Influences Survival. Leukemia 2006; 20: 42-47.
ALL
Bergfelt E, Kozlowski P, Ahlberg L, Hulegårdh E, Hägglund H, Karlsson K,
Markuszewska-Kuczymska A, Tomaszewska-Toporska B, Smedmyr B, Åström M, Amini RM,
Hallböök H. Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal
residual disease (MRD) monitoring in older patients withPhiladelphia-negative B cell precursor
acute lymphoblastic leukaemia: a Swedish registry-based study. Med Oncol. 2015
Apr;32(4):135. doi:10.1007/s12032-015-0582-2. Epub 2015 Mar 22. PubMed PMID: 25796502.
Hulegårdh E, Hägglund H, Ahlberg L, Karlsson K, Karbach H, Markuszewska A, Persson I, Åström
M, Hallböök H. Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic
leukemia in Sweden: a population-based study. Med Oncol. 2014 Aug;31(8):66. doi:
10.1007/s12032-014-0066-9. Epub 2014 Jun 26.
Kozlowski P, Åström M, Ahlberg L, Bernell P, Hulegårdh E, Hägglund H, Karlsson K,
Markuszewska-Kuczymska A, Tomaszewska-Toporska B, Smedmyr B, Amini RM, Hallböök H;
Swedish Adult ALL Group. High relapse rate of T cell acute lymphoblastic leukemia in adults
treated with Hyper-CVAD chemotherapy in Sweden. Eur J Haematol. 2014;92(5):377-81. doi:
10.1111/ejh.12269. Epub 2014 Feb 21
Kozlowski P, Åström M, Ahlberg L, Bernell P, Hulegårdh E, Hägglund H, KarlssonK, MarkuszewskaKuczymska A, Tomaszewska-Toporska B, Smedmyr B, Hallböök H. High curability via intensive
reinduction chemotherapy and stem cell transplantationin young adults with relapsed acute
lymphoblastic leukemia in Sweden 2003-2007.Haematologica. 2012 Sep;97(9):1414-21. doi:
10.3324/haematol.2011.057851. Epub2012 Apr 17. PubMed PMID: 22511497; PubMed Central
PMCID: PMC3436244.
Juliusson G, Karlsson K, Hallböök H. Population-based analyses in adult acute lymphoblastic
leukemia. Blood 2010; Aug 12;116(6):1011
Juliusson G, Karlsson K, Lazarevic VLj, Wahlin A, Brune M, Antunovic P, DerolfA, Hägglund H, Karbach
H, Lehmann S, Möllgård L, Stockelberg D, Hallböök H,Höglund M; Swedish Acute Leukemia Registry
Group, the Swedish Acute MyeloidLeukemia Group, the Swedish Adult Acute Lymphoblastic
Leukemia Group. Hematopoietic stem cell transplantation rates and long-term survival in
acutemyeloid and lymphoblastic leukemia: real-world population-based data from theSwedish
Acute Leukemia Registry 1997-2006. Cancer. 2011 Sep 15;117(18):4238-46.doi:
10.1002/cncr.26033. Epub 2011 Mar 8. PubMed PMID: 21387283.
Lymfom
Glimelius I, Ekberg S, Linderoth J, Jerkeman M, Chang ET, Neovius M, Smedby KE. Sick leave and
disability pension in Hodgkin lymphoma survivors by stage, treatment and follow-up time - a
population-based comparative study. Journal of Cancer Survivorship In Press 2015
Ellin F, Jerkeman M, Hagberg H, Relander T. Treatment outcome in T-cell lymphoblastic
lymphoma in adults - a population-based study from the Swedish Lymphoma Registry. Acta
Oncol. 2014 Jul;53(7):927-34. PMID: 24913153
Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM,
D'Amore F, Nilsson-Ehle H, Jensen P, Pedersen M, Geisler CH, Jerkeman M. Real world data on
primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
Blood. 2014 Aug 21;124(8):1288-95. PMID: 24859361
Székely E, Hagberg O, Arnljots K, Jerkeman M. Improvement in survival of diffuse large B-cell
lymphoma in relation to age, gender, International Prognostic Index and extranodal
presentation: a population based Swedish Lymphoma Registry study. Leuk Lymphoma. 2014
Aug;55(8):1838-43. PMID: 24138330
Junlén HR, Peterson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H, Erlanson M, Hagberg H,
Rådlund A, Hagberg O, Wahlin BE. Follicular lymphoma in Sweden: nationwide improved
survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry
Study. Leukemia. 2014 Aug 25. PMID: 25151959
Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and
treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry
Blood. 2014 Sep 4;124(10):1570-7. PMID: 25006130
Hedström G, Hagberg O, Jerkeman M, Enblad G; on behalf of the Swedish Lymphoma Study
Group. The impact of age on survival of diffuse large B-cell lymphoma - a population-based
study. Acta Oncol. 2014 Dec 18:1-8. PMID: 25519707
Juliusson G, Samuelsson H, and the Swedish Lymphoma Registry. Hairy Cell Leukemia:
Epidemiology, pharmacokinetics of cladribine and long-term follow-up of subcutaneous
therapy. Leuk Lymphoma 2011; Jun;52 Suppl 2:46-9.
Abrahamsson A, Dahle N, Jerkeman M. Marked improvement of overall survival in mantle cell
lymphoma: a population based study from the Swedish Lymphoma Registry. Leuk Lymphoma.
2011 Oct;52(10):1929-35. PMID: 21702648
Wästerlid T, Jonsson B, Hagberg H, Jerkeman M. Population based study of prognostic factors
and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk
Lymphoma. 2011 Nov;52(11):2090-6. PMID: 21718134
KML
Gunnarsson N ee al, Second malignancies following treatment of chronic myeloid leukaemia in the
tyrosine kinase inhibitor era. Br J Haematol. 2015 Jun;169(5):683-8.
Hoglund M et al,. Epidemiology of Chronic Myeloid Leukemia - an Update Ann Hematol. 2015
Apr;94 Suppl 2:S241-7.
Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M, Dreimane A, Ekblom M,
Lehmann S, Ljungman P, Malm C, Markevarn B, Myhr-Eriksson K, Ohm L, Olsson-Stromberg U,
Sjalander A, Wadenvik H, Simonsson B, Stenke L, Richter J. Tyrosine kinase inhibitor usage,
treatment outcome, and prognostic scores in CML: report from the population-based Swedish
CML registry. Blood. 2013 Aug 15;122(7):1284-92.
MPN
Pettersson H1, Knutsen H, Holmberg E, Andréasson B. Increased incidence of another cancer in
myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol. 2015
Feb;94(2):152-6. doi: 10.1111/ejh.12410. Epub 2014 Jul 24.